There is a peculiar moral arithmetic attached to weight loss in American culture. Lose weight through exercise and the story is discipline. Do it through dieting and the story is restraint. Endure enough hunger, enough early mornings, enough denial, and the result can be treated as evidence of character.
Take a medication that makes the process easier, however, and suddenly the language can change.
Cheating. Taking the easy way out. Cutting corners.
A new study led by Florida State University assistant professor Braidyn Lazenby gives that language a revealing context. Published in Health Communication, the research examined open-ended, one-on-one interviews with 34 adults taking GLP-1 medications including drugs used for weight management, metabolic disorders and other health conditions. Researchers found that participants frequently encountered stigma not from anonymous strangers but within their own social circles - among friends, family members and romantic partners.
That distinction matters because social stigma does not have to be aimed directly at someone to teach them a lesson. One person can make a casual remark about somebody else being “obviously on the jab.” A friend can dismiss another person’s weight loss as medication-assisted and therefore somehow less legitimate. Nobody has to turn toward the GLP-1 user in the room. The message has already arrived: this is information about yourself that may change how I see you.
According to Florida State University’s summary of the findings, some participants responded by concealing their medication use, minimizing the medication’s role in their weight loss, hesitating to discuss GLP-1s with healthcare providers, or feeling compelled to explain that they had an underlying medical reason for taking the drug.
That is an extraordinary amount of social negotiation around a prescription.
The researchers describe part of the problem as a “weight bias paradox.” People can be judged for living in a larger body and then judged again for using a medication that changes it. Even participants who were not taking a GLP-1 primarily for weight loss described similar stigma-management behavior.
The paradox exposes something larger than the current cultural argument over Ozempic, Wegovy or Zepbound. We have not simply developed opinions about these medications. We have built an unofficial rulebook around what kinds of bodily change deserve respect. And that raises the obvious question: if weight loss is not a competition, how can taking medication be cheating?
Cheating requires a game. It requires agreed-upon rules, a recognized objective and some advantage gained by violating those rules. Yet everyday conversations about weight often borrow the language of sports and morality anyway. People “earn” results. They “put in the work.” They demonstrate willpower. Someone who receives medical assistance can then be treated as if they skipped a required portion of the contest.
But there is no referee. There is no medal ceremony. There is no universally legitimate path that every body is required to follow.
What the study captures especially well is how quickly those imagined rules become social information. People are constantly learning what is safe to disclose by listening to how the people around them talk about others. We do this with careers, money, relationships, illness, addiction, parenting and almost every other part of private life. A judgment delivered about an absent third person can function as a warning to everyone still in the room.
That makes the GLP-1 conversation unusually instructive. A friend who says, “I would never take that stuff,” may believe they are merely expressing a personal preference. Someone quietly taking the medication may hear something different: I should probably not tell you.
The consequence is not simply hurt feelings. The study is about communication - about how anticipated judgment changes what people say, what they conceal and how they explain themselves. Its sample is small and qualitative, so it is not designed to tell us how common these experiences are across the entire population of GLP-1 users. What it does provide is a close view of how stigma can operate inside ordinary relationships.
That may also explain why justification becomes such a prominent response. Participants sometimes emphasized an underlying health condition as though medical necessity could move them into a more socially acceptable category. The distinction quietly creates another hierarchy: taking a GLP-1 for diabetes or another metabolic condition can be framed as legitimate, while taking it for weight management may require a defense.
But even that distinction becomes unstable. The researchers found that people taking the medications for reasons other than weight loss could still experience the same weight-related stigma and use similar strategies to manage it. Once a medication becomes culturally associated with body size, its meaning can outrun the reason an individual person is actually taking it.
That is the strange thing about stigma. It simplifies complicated lives so that judgment can move faster.
There are legitimate medical questions surrounding GLP-1 medications, and treatment decisions belong in conversations between patients and qualified healthcare professionals. People can discuss side effects, access, cost, prescribing practices and long-term care without turning another person’s body into a referendum on character. Medical scrutiny and moral scrutiny are not the same thing.
Yet popular conversation frequently slides from one into the other. A discussion about medication becomes a discussion about whether someone “deserved” their result. Concern about health becomes speculation about somebody else’s discipline. Curiosity becomes surveillance.
The Florida State University research suggests the people hearing those conversations may be closer than we think.
They may be a friend at dinner. A coworker listening quietly. A person on the other side of the couch. Someone who has already heard enough to decide that explaining their healthcare choices is more trouble than keeping them private.
Perhaps that is the most useful part of the study. It reminds us that social norms are not transmitted only through direct confrontation. We build them casually, sentence by sentence, while talking about people who are not there.
And sometimes the person we are actually teaching is sitting right beside us.
SOURCE NOTES
• Source note: This article is based on Florida State University’s Sept. 24, 2026 release about the study “They Call Us Cheaters: Exploring Stigma Management Communication Strategies During GLP-1 Medication Use,” published online Sept. 18, 2026 in Health Communication. The study used reflexive thematic analysis of interviews with 34 GLP-1 users. DOI: 10.1080/10410236.2026.2734167.
Study findings attributed to Florida State University's release and the Health Communication paper cited in SOURCE NOTES. Cultural framing is RMN's.